Integration of molecular imaging in the personalized approach to neuroendocrine tumors
- 1 May 2022
- journal article
- research article
- Published by Edizioni Minerva Medica in The Quarterly Journal of Nuclear Medicine and Molecular Imaging
- Vol. 66 (2), 116-129
- https://doi.org/10.23736/s1824-4785.22.03431-8
Abstract
Article: Integration of molecular imaging in the personalized approach to neuroendocrine tumours - The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 Mar 03 - Minerva Medica - JournalsKeywords
This publication has 65 references indexed in Scilit:
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Promising Therapeutic Targets in NeuroblastomaClinical Cancer Research, 2012
- Radiopeptide Imaging and Therapy in EuropeJournal of Nuclear Medicine, 2011
- I-131-MIBG therapiesMethods, 2011
- Safety and efficacy of tandem 131I‐metaiodobenzylguanidine infusions in relapsed/refractory neuroblastomaPediatric Blood & Cancer, 2011
- 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- 131I-Metaiodobenzylguanidine Therapy of Neuroblastoma and Other Neuroendocrine TumorsSeminars in Nuclear Medicine, 2010
- Comparison of Iodine-123 Metaiodobenzylguanidine (MIBG) Scan and [18F]Fluorodeoxyglucose Positron Emission Tomography to Evaluate Response After Iodine-131 MIBG Therapy for Relapsed NeuroblastomaJournal of Clinical Oncology, 2009
- 111In-Octreotide Is Superior to 123I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck ParagangliomasJournal of Nuclear Medicine, 2008
- Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory NeuroblastomaJournal of Clinical Oncology, 2007